Skip to main content

Table 1 Baseline characteristics of patients with thymic epithelial tumor

From: Apatinib in patients with recurrent or metastatic thymic epithelial tumor: a single-arm, multicenter, open-label, phase II trial

Characteristic

Apatinib (n = 25)

Sex, n (%)

 Male

17 (68)

 Female

8 (32)

Age, years

 Median (range)

53 (26–70)

 ≥60, n (%)

7 (28)

 <60, n (%)

18 (72)

Smoking history, n (%)

 Yes

10 (40)

 No

15 (60)

Histology, n (%)

 Thymic carcinoma

15 (60)

 Thymoma

10 (40)

Masaoka’s stage, n (%)

 IVa

4 (16)

 IVb

21 (84)

Number of prior therapy lines

 1, n (%)

12 (48)

 ≥2, n (%)

13 (52)

ECOG performance status, n (%)

 0

4 (16)

 1

21 (84)

Number of metastatic lesions, n (%)

 1

5 (20)

 ≥2

20 (80)

  1. ECOG Eastern Cooperative Oncology Group